Zacks Investment Research disclosed Cempra Inc (NASDAQ:CEMP), hiking its price target to $25.00 earlier today
- Updated: October 16, 2016
Boasting a price of $22.20, Cempra Inc (NASDAQ:CEMP) traded -2.70% lower on the day. With the last stock price close up 9.62% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Cempra Inc has recorded a 50-day average of $23.24 and a two hundred day moving average of $19.72. 593,560 shares of the stock were exchanged, down from an avg. volume of 867,923
Stating a potential upside of 0.13%, Zacks Investment Research raised the target price of Cempra Inc (NASDAQ:CEMP) to $25.00
On 9/13/2016, Raymond James released a statement for Cempra Inc (NASDAQ:CEMP) bumped up the target price from $0.00 to $32.00 that suggested an upside of 0.41%.
With a total market value of $0, Cempra Inc has with a one year low of $14.03 and a one year high of $34.24 .
A total of 12 equity analysts have released a ratings update on CEMP. Five equity analysts rating the company a strong buy, six equity analysts rating the company a buy, two equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $38.75.
Brief Synopsis About Cempra Inc (NASDAQ:CEMP)
Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. Solithromycin has therapeutic potential and the spectrum of activity to target pathogenic bacteria. The Company also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.